CHARACTERISTICS OF RELAPSES AFTER SURGICAL AND COMBINED TREATMENT FOR NON-SMALL CELL LUNG CANCER
Vol. 63 No. 4 (2017), ORIGINAL ARTICLES. A. PROTOCOLS OF CLINICAL RESEARCH
Vol. 63 No. 4 (2017)

CHARACTERISTICS OF RELAPSES AFTER SURGICAL AND COMBINED TREATMENT FOR NON-SMALL CELL LUNG CANCER

ORIGINAL ARTICLES. A. PROTOCOLS OF CLINICAL RESEARCH
https://doi.org/10.37469/0507-3758-2017-63-4-639-644
Published 01.04.2017
Vladimir Solodkiy
Russian Scientific Center of Roentgenoradiology
Vladimir Sotnikov
Russian Scientific Center of Roentgenoradiology
Vladimir Kharchenko
Russian Scientific Center of Roentgenoradiology
Vladimir Chkhikvadze
Russian Scientific Center of Roentgenoradiology
Georgiy Panshin
Russian Scientific Center of Roentgenoradiology
Nikolay Nudnov
Russian Scientific Center of Roentgenoradiology
Aleksandr Morgunov
Russian Scientific Center of Roentgenoradiology
S. Trotsenko
Russian Scientific Center of Roentgenoradiology
PDF (Русский)

Keywords

LUNG CANCER
SURGICAL TREATMENT
POSTOPERATIVE RADIATION THERAPY
RELAPSES CHARACTERISTIC

How to Cite

Solodkiy, V., Sotnikov, V., Kharchenko, V., Chkhikvadze, V., Panshin, G., Nudnov, N., Morgunov, A., & Trotsenko, S. (2017). CHARACTERISTICS OF RELAPSES AFTER SURGICAL AND COMBINED TREATMENT FOR NON-SMALL CELL LUNG CANCER. Voprosy Onkologii, 63(4), 639–644. https://doi.org/10.37469/0507-3758-2017-63-4-639-644
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Abstract

Postoperative radiation therapy (PORT) in the combined treatment of non-small cell lung cancer (NSCLC) can improve the locoregional control of the disease regardless of the prevalence of tumor and improve the survival rates for the IIA-IIIB stage NSCLC compared with the surgical method alone. For more accurate assessment of the role of PORT the comparative analysis of the relapses structure after combined modality and surgical treatment of NSCLC was carried out.
https://doi.org/10.37469/0507-3758-2017-63-4-639-644
PDF (Русский)

References

Вальков М.Ю., Скрипач Ю.В., Соловьева Е.П. и др. Методы лечения и исходы при местно-распространенном раке легкого III стадии: популяционный анализ // Вестник РНЦРР. - 2014. - Vol. 9. - 9 с.

Солодкий В.А., Харченко В.П., Чхиквадзе В.Д. и др. Результаты хирургического и комбинированного лечения немелкоклеточного рака легкого с послеоперационной лучевой терапией в режиме гипофракционирования. сообщение II. безрецидивная выживаемость и выживаемость без локорегионарного рецидива // Вопросы онкологии. - 2016. - Т. 62. - № 1. - С. 72-78.

Харченко В.П., Кузьмин И.В. Рак легкого. Руководство для врачей // Москва: Медицина, 1994. - 92 с.

Харченко В.П., Чхиквадзе В.Д. Хирургическое и комбинированное лечение немелкоклеточного рака легкого // Вопросы онкологии. - 2009. - Vol. 55. - № 4. - С. 455-458.

al-Kattan K., Sepsas Е., Fountain S.W. Townsend E.R. Disease recurrence after resection for stage I lung cancer // Eur. J. Cardiothorac. Surg. - 1997. - Vol. 12. - № 3. - P. 380-384.

Bakira M., Fraser S., RoutledgeIs Т., Scarcic M. Is surgery indicated in patients with stage IIIa lung cancer and mediastinal nodal involvement? // Interact. Cardiovasc. Thorac. Surg. - 2011. - Vol. 13. - P. 303-310.

Consonni D., Pierobon M., Gail M.H. et al. Lung Cancer Prognosis Before and After Recurrence in a Population-Based Setting // J. Natl. Cancer Inst. - 2015. - Vol. 107. - № 6. - P 1-12.

Douillard J.Y, Rosell R., De Lena M. et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomised controlled trial // Lancet Oncol. - 2006. - Vol. 7. - № 9. - P. 719-727.

Higgins K.A., Chino J.P, Berry M. et al. Local failure in resected N1 lung cancer: implications for adjuvant therapy // Int. J. Radiat. Oncol. Biol. Phys. - 2012. - Vol. 83. -№2. - P. 727-733.

Jemal A., Bray F Center M.M et al. Global cancer statistics // CA Cancer. J. Clin. - 2011. - Vol. 61. - P 69-90.

Kelsey C.R., Marks L.B., Hollis D. et al. Local recurrence after surgery for early stage lung Cancer: An 11-year experience with 975 patients // Cancer. - 2000. - Vol. 115. - P 5218-5227.

Koo H.K., Jin S.M., Lee C.H. et al. Factors associated with recurrence in patients with curatively resected stage I-II Lung Cancer // Lung Cancer. - 2011. - Vol. 73. - P 222-229.

Maeda R., Yoshida J., Ishii G. et al. Risk factors for tumor recurrence in patients with early-stage (stage I and II) non-small cell lung cancer: Patient selection criteria for adjuvant chemotherapy according to the 7th edition TNM classification // Chest. - 2011. - Vol. 140. - P. 1494-1502.

Nakagawa Т., Okumura N., Ohata K. et al. Postrecurrence survival in patients with stage I non-small cell lung cancer // Eur. J. Cardiothorac. Surg. - 2008. - Vol. 34. - P. 499-504.

PORT Meta-analysis Trialists Group. Postoperative radiotherapy for non-small-cell lung cancer // Lang cancer. - 2005. - Vol. 47. - P. 81-83.

Saisho S., Yasuda K., Maeda A. et al. Post-recurrence survival of patients with non-small-cell lung cancer after curative resection with or without induction/adjuvant che motherapy // Interact Cardiovasc Thorac Surg. - 2013. - Vol. 16. - P. 166-172.

Shen W., Ji J., Zuo Y et al. Comparison of efficacy for postoperative chemotherapy and concurrent radiochemotherapy in patients with IIIA-pN2 non-small cell lung cancer: An early closed randomized controlled trial // Radiotherapy and Oncology. - 2014. - Vol. 110. -1. - P. 120-125.

Sugimura H., Nichols F.C., Yang P et al. Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection // Ann. Thorac. Surg. - 2007. - Vol. 83. - P. 409-417.

Varlotto J.M., Yao A.N., DeCamp M.M. et al. Nodal stage of surgically resected non-small cell lung cancer and its effect on recurrence patterns and overall survival // Int. J. Radiat. Oncol. Biol. Phys. - 2015. - Vol. 91. - № 4. - P 765-773.

Yano T., Haro A., Yoshida T et al. Prognostic impact of local treatment against postoperative oligometastases in nonsmall cell lung cancer // J. Surg. Oncol. - 2010. - Vol. 102. - P 852-855.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

© АННМО «Вопросы онкологии», Copyright (c) 2017